Causes and Risk Factors for Acute Myeloid Leukemia

Key Takeaways

• AML develops when genetic mutations disrupt normal myeloid cell development in the bone marrow.
• Chromosomal abnormalities, including translocations and deletions, are among the most significant genetic factors linked to AML.
• Exposure to ionizing radiation, benzene, and certain chemotherapy agents increases AML risk substantially.
• Age, sex, and pre-existing blood disorders are established demographic and clinical risk factors.
• Most AML cases arise without a clearly identifiable single cause, involving a combination of genetic and environmental triggers.

What Causes Acute Myeloid Leukemia (AML)?

AML arises when immature myeloid cells in the bone marrow acquire somatic mutations that disrupt normal differentiation and proliferation. Rather than maturing into functional red blood cells, white blood cells, or platelets, these abnormal cells—called blasts—accumulate rapidly and crowd out healthy cells. The disease progresses quickly, which is why it is classified as “acute.”

At its core, AML is a disease of DNA damage. Mutations can occur spontaneously, or they can be triggered by external exposures or inherited predispositions. Genes such as FLT3, NPM1, CEBPA, and IDH1/IDH2 are frequently mutated in AML and play critical roles in regulating blood cell development. According to the American Cancer Society, AML accounts for roughly 31% of all leukemia cases in adults, with approximately 20,800 new cases diagnosed annually in the United States.

It is important to note that in many patients, no single definitive cause can be identified. AML typically results from an accumulation of multiple molecular events over time rather than one isolated trigger. This complexity makes the disease challenging to predict or prevent in every individual case.

Genetic and Chromosomal Factors Linked to AML

Genetic factors linked to acute myeloid leukemia represent one of the most thoroughly studied areas of AML research. Chromosomal abnormalities—structural changes in the DNA of myeloid cells—are detected in approximately 50–60% of adult AML cases and carry significant prognostic value. These abnormalities include translocations, inversions, and deletions that alter gene expression and disrupt normal cell cycle regulation.

Among the most well-characterized chromosomal changes is the translocation between chromosomes 8 and 21, written as t(8;21), which fuses the RUNX1 and RUNX1T1 genes. Similarly, inversion of chromosome 16—inv(16)—disrupts the CBFB gene. Both alterations are associated with a relatively favorable prognosis. In contrast, monosomy 7 and complex karyotypes, which involve three or more chromosomal abnormalities, are linked to poorer treatment outcomes.

Beyond structural chromosomal changes, point mutations in individual genes also drive AML development. Mutations in FLT3 are found in about 30% of AML patients and promote uncontrolled cell proliferation. NPM1 mutations, present in approximately 25–30% of cases, affect nuclear protein transport and are frequently associated with a normal karyotype. Inherited germline mutations in genes such as RUNX1, GATA2, and CEBPA can also predispose individuals to familial AML, though inherited forms remain relatively rare compared to sporadic cases.

Certain inherited syndromes elevate AML risk considerably. Down syndrome (trisomy 21), Fanconi anemia, Bloom syndrome, and Diamond-Blackfan anemia are all associated with a substantially higher lifetime risk of developing AML. Children with Down syndrome, for example, are estimated to have a 10- to 20-fold greater risk of leukemia compared to the general pediatric population, according to the National Cancer Institute.

Environmental and Lifestyle Causes and Risk Factors for Acute Myeloid Leukemia

Environmental causes of acute myeloid leukemia have been identified through decades of epidemiological research and occupational health studies. Exposure to ionizing radiation is among the most firmly established external risk factors. Survivors of atomic bomb detonations in Hiroshima and Nagasaki showed significantly elevated AML rates, and individuals who receive high-dose radiation therapy for other cancers also face increased risk.

Benzene, an industrial chemical found in cigarette smoke, gasoline, and certain manufacturing processes, is a well-documented leukemogen. Prolonged occupational exposure to benzene—common in rubber, petroleum, and chemical industries—has been consistently linked to AML development. The International Agency for Research on Cancer (IARC) classifies benzene as a Group 1 carcinogen, meaning there is sufficient evidence of its cancer-causing potential in humans.

Prior treatment with certain chemotherapy drugs, particularly alkylating agents (such as cyclophosphamide and melphalan) and topoisomerase II inhibitors (such as etoposide), can lead to therapy-related AML, also referred to as secondary AML. This form of the disease typically emerges five to ten years after initial chemotherapy exposure and often carries a less favorable prognosis than de novo AML.

Cigarette smoking is another modifiable risk factor. Tobacco smoke contains benzene and other carcinogenic compounds that enter the bloodstream and reach the bone marrow. Research published by the American Cancer Society estimates that smokers have approximately a 40% higher risk of developing AML compared to non-smokers. Obesity has also been associated with modestly elevated AML risk, though the biological mechanism is less clearly defined than for radiation or benzene exposure.

Risk Factor	Type	Evidence Level
Ionizing radiation exposure	Environmental	Strong (epidemiological and clinical data)
Benzene exposure	Environmental / Occupational	Strong (IARC Group 1 carcinogen)
Prior chemotherapy (alkylating agents, topoisomerase II inhibitors)	Medical / Treatment-related	Strong (clinical studies)
Cigarette smoking	Lifestyle	Moderate to strong
Chromosomal abnormalities (e.g., t(8;21), inv(16))	Genetic	Strong (cytogenetic data)
Inherited syndromes (Down syndrome, Fanconi anemia)	Genetic / Hereditary	Strong (clinical and genetic studies)
Pre-existing blood disorders (MDS, MPN)	Clinical	Strong (hematological evidence)
Obesity	Lifestyle	Moderate

Who Is Most at Risk for Developing Acute Myeloid Leukemia?

Several demographic and clinical characteristics define population groups with the highest AML burden. Age is the most significant non-modifiable risk factor: the median age at diagnosis is approximately 68 years, and incidence rises sharply after age 60. According to the Surveillance, Epidemiology, and End Results (SEER) database maintained by the National Cancer Institute, AML incidence in individuals over 65 is nearly five times higher than in younger adults.

Sex also plays a role. AML is slightly more common in males than females across most age groups, though the reasons for this difference are not fully understood and may involve hormonal, occupational, and genetic variables. White and Hispanic populations show higher AML incidence rates compared to Black and Asian populations in U.S. data, though disparities in access to diagnostic care may contribute to differences in reported rates.

Individuals with pre-existing hematologic conditions carry a substantially elevated risk. Myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN)—including polycythemia vera and essential thrombocythemia—can progress to AML over time. This transformation is sometimes called secondary or evolved AML and tends to be more difficult to treat than de novo disease. Regular monitoring of patients with these conditions is therefore clinically critical.

A family history of AML or other hematologic malignancies may modestly increase individual risk, particularly when a germline predisposition syndrome is present. However, most AML cases are sporadic, meaning they occur in individuals without a notable family history. The combination of advancing age, cumulative environmental exposures, and the gradual acquisition of somatic mutations over a lifetime is the most common scenario underlying AML development in the general population.

Frequently Asked Questions

Is acute myeloid leukemia hereditary?

Most AML cases are not hereditary and arise from spontaneous somatic mutations rather than inherited gene changes. However, a small subset of patients carry germline mutations in genes such as RUNX1, GATA2, or CEBPA, or have inherited syndromes like Fanconi anemia or Down syndrome that significantly elevate risk. Genetic counseling is recommended when a strong family history of hematologic malignancies or a known predisposition syndrome is identified.

Can lifestyle changes reduce the risk of developing AML?

While AML cannot be fully prevented, certain modifiable factors can lower risk. Avoiding tobacco smoke reduces exposure to benzene and other carcinogens linked to AML. Limiting contact with industrial chemicals and following workplace safety protocols for radiation or chemical exposure also helps. Maintaining a healthy body weight may offer modest protective benefit. These measures reduce overall cancer risk but cannot guarantee prevention, particularly in individuals with strong genetic predispositions.

How does prior cancer treatment increase AML risk?

Certain chemotherapy drugs, especially alkylating agents and topoisomerase II inhibitors, damage DNA in bone marrow cells and can trigger secondary mutations that lead to therapy-related AML. This form of AML typically appears five to ten years after initial treatment. Radiation therapy, particularly to large areas of the body, carries a similar risk. Oncologists weigh these long-term risks carefully when designing treatment plans for other cancers, especially in younger patients with longer life expectancies.